Modus Therapeutics will present new research on sevuparin for chronic kidney disease (CKD) with anemia at the 32nd Symposium on Glycosaminoglycans, held 18–20 September at Villa Vigoni, Italy. Professor Maura Poli of the University of Brescia will deliver the presentation, showcasing joint data from Modus and Brescia. The company has also presented new data at BioIron and EHA 2025, further supporting sevuparin’s differentiated profile. CEO John Öhd said: “With the development of sevuparin, Modus is a pioneer in developing medicines from the unique carbohydrate (sugar)-based group of biomolecules known as glycosaminoglycans (GAGs). “Receiving attention at an international GAG summit underscores the molecule’s distinctive profile and clinical potential — and it comes as we move into the next step of our phase 2 program.”